BioCentury
ARTICLE | Company News

KeyNeurotek, Bayer CNS deal

July 1, 2005 1:08 AM UTC

Bayer (FSE:BAYG; BAY) granted KeyNeurotek (Magdeburg, Germany) an exclusive license to its Bay 38-7271 cannabinoid receptor agonist to treat traumatic brain injury. The compound has completed Phase I ...